Genmab A (GMAB) Asset Writedowns and Impairment (2023 - 2026)

Genmab A's Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $150.0 million for Q1 2026.

• Quarterly Asset Writedowns and Impairment rose 14900.0% year-over-year to $150.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $153.0 million (up 410.0% YoY) and the FY2025 annual result came in at $32.0 million, up 88.24% from the prior year.
• Asset Writedowns and Impairment was $150.0 million for Q1 2026 at Genmab A, up from $1.0 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $254.0 million in Q4 2023 and bottomed at $1.0 million in Q1 2025.
• A 4-year average of $54.5 million and a median of $9.0 million in 2024 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2025 — Asset Writedowns and Impairment tumbled 90.91% — and 2026, when it surged 14900.0%.
• Genmab A's Asset Writedowns and Impairment stood at $254.0 million in 2023, then plunged by 95.67% to $11.0 million in 2024, then tumbled by 90.91% to $1.0 million in 2025, then jumped by 14900.0% to $150.0 million in 2026.
• Business Quant data shows GMAB's Asset Writedowns and Impairment at $150.0 million in Q1 2026, $1.0 million in Q3 2025, and $1.0 million in Q2 2025.